![vsm cryptocurrency ticker vsm cryptocurrency ticker](https://i.ebayimg.com/images/g/eyoAAOSwSaNfUeU7/s-l1600.jpg)
Versum stock currently trades at more than $50 dollars-higher than Merck KGaA’s bid and more than $10 higher than the value implied by the Entegris exchange ratio. Looking ahead: Versum already rejected Merck KGaA’s offer once and isn’t likely to be amenable to a hostile bid.īut it isn’t clear what Versum shareholders should do-or even what they expect. Versum and Merck KGaA weren’t immediately available for comment. “Merck’s low premium, change-in-control offer would prevent the stockholders of both companies from participating in potential upside of the combined company,” Entegris added. Versum stock closed Monday at $49.67.Įntegris told Barron’s on Tuesday that its “merger of equals” with Versum will create significant value for stockholders of both companies because of its strategic benefits and expected cost and revenue synergies. Merck KGaA hopes a majority of shareholders will take the cash, giving them control of Versum. The company has credit facilities in place and will pay any shareholder $48 a share for their stock. Merck KGaA has no affiliation with the U.S.-based Merck (MRK). Versum believes its shareholders will do better over time owning the combined Versum-Entegris than by taking a one-time cash payment from the German pharmaceutical and chemical company.
![vsm cryptocurrency ticker vsm cryptocurrency ticker](https://images.cointelegraph.com/images/1434_aHR0cHM6Ly9zMy5jb2ludGVsZWdyYXBoLmNvbS9zdG9yYWdlL3VwbG9hZHMvdmlldy9kMDRkZDg1YWQ4YmI5OGEwZjRiNDM4MmIwYWRiYjA0Yy5qcGc=.jpg)
Merck KGaA attempted to break up the deal in late February by offering $48 in cash for each Versum share, but Versum rejected the offer.